The spindle assembly checkpoint (SAC) maintains genomic stability by delaying chromosome segregation until the last chromosome has attached to the mitotic spindle. The SAC prevents the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase from recognizing cyclin B and securin by catalysing the incorporation of the APC/C co-activator, CDC20, into a complex called the mitotic checkpoint complex (MCC). The SAC works through unattached kinetochores generating a diffusible 'wait anaphase' signal 1,2 that inhibits the APC/C in the cytoplasm, but the nature of this signal remains a key unsolved problem. Moreover, the SAC and the APC/C are highly responsive to each other: the APC/C quickly targets cyclin B and securin once all the chromosomes attach in metaphase, but is rapidly inhibited should kinetochore attachment be perturbed 3, 4 . How this is achieved is also unknown. Here, we show that the MCC can inhibit a second CDC20 that has already bound and activated the APC/C. We show how the MCC inhibits active APC/C and that this is essential for the SAC. Moreover, this mechanism can prevent anaphase in the absence of kinetochore signalling. Thus, we propose that the diffusible 'wait anaphase' signal could be the MCC itself, and explain how reactivating the SAC can rapidly inhibit active APC/C.
The MCC is an APC/C inhibitor containing the MAD2, BUBR1 and BUB3 checkpoint proteins in a complex with CDC20 5 , where MAD2 and BUBR1 inhibit CDC20 by binding to substrate and APC/C recognition motifs [6] [7] [8] . To elucidate how the SAC inhibits the APC/C we produced recombinant human MCC (rMCC) by co-expressing His 6 -tagged MAD2, streptavidin binding protein (SBP)-tagged BUBR1 and untagged CDC20 at a 8:1:2 ratio (Extended Data Fig. 1a-e ) in baculovirus-infected Sf9 cells. We co-purified MAD2, BUBR1 and CDC20 in a 'core MCC' complex at a 1:1:1 ratio (Extended Data Fig. 1b ).
Incubating core rMCC with recombinant His 6 -tagged CDC20 showed that core MCC could bind a second CDC20 molecule ( Fig. 1a and Extended Data Fig. 1f ), which was not due to CDC20 homodimerizing ( Fig. 1a ). Including BUB3 in the core rMCC made no difference to the amount of CDC20 that was bound (Extended Data Fig. 2 ). We note here recent speculation that the MCC may contain two molecules of CDC20 9 . The mode of binding to the second CDC20 differed from that required to form the core MCC because core MCC could bind to a CDC20 DKILR mutant unable to bind MAD2 8 (Fig. 1a and Extended Data Fig. 1c ). This also excluded the possibility that the second CDC20 had exchanged with CDC20 in the core MCC. 1 The Gurdon Institute and Department of Zoology, Tennis Court Road, Cambridge CB2 1QN, UK. 
APC/C ΔCDC20 -pre-SBP CDC20 rMCC assay. 6His-SBP CDC20 or rMCC, composed of untagged CDC20, SBP BUBR1 and 6His MAD2 were incubated with streptavidin (strep.) beads, unbound proteins washed away, and the beads incubated with either wild-type (WT) or DKILR (K 129 ILR/AAAA) mutant 6His CDC20 (Extended Data Fig. 1f ). Proteins retained on the streptavidin beads were analysed by quantitative immunoblotting. Molecular mass markers are on the left; kDa, kilodalton. b, c, MCC prefers to bind APC/C CDC20 . The APC/C was immunoprecipitated from CDC20-depleted mitotic extracts supplemented with a constant amount of core MCC, and increasing amounts of SBP CDC20 (b), or vice versa (c), and analysed as in a. IP, immunoprecipitate. d, The MCC is an APC/C CDC20 inhibitor. The APC/C was immunoprecipitated as in b and incubated with infrared-dye-conjugated securin in an ubiquitylation reaction at 37 uC for 15 or 30 min with core rMCC and/or SBP CDC20 (1.5:1 ratio of core rMCC to rCDC20, see Extended Data Fig. 3a, b ). Securin ubiquitylation (securin-ubi n ) was analysed by SDS-PAGE and a Li-COR Odyssey scanner. The amount of unconjugated securin is shown below the panel (level at 0 min is set to 1.0). e-g, The MCC inhibits active APC/C. e, The APC/C DCDC20 was pre-incubated with SBP CDC20 to form APC/C CDC20 , unbound SBP CDC20 washed away, and APC/C CDC20 activity assayed as in panel d for 30 min. A 10-fold excess of rMCC to immunoprecipitated APC/C was added at 0 min (see also Extended Data Fig. 3c ). f, APC/C activity was assayed as in e except that rMCC was added 5 min after starting the reaction. g, Unconjugated securin was measured from three independent experiments and the mean and s.d. plotted against time. To estimate APC/C inhibition, the level of securin at 5 min was set to 1.0. All results in Fig. 1 are representative of three or more experiments.
The question arose as to why we could not purify rMCC with two molecules of CDC20. We postulated that the second CDC20 bound less stably than the first CDC20, which is cooperatively bound by MAD2 and BUBR1 6 ; therefore, limited amounts of CDC20 would preferentially incorporate into the core MCC. In agreement with this, we purified some core rMCC bound to a second CDC20 from Sf9 cell lysates containing excess CDC20 (50% bound in Extended Data Fig. 1g ). We noted that increasing the amount of functional SBP CDC20 enhanced core rMCC binding to the APC/C ( Fig. 1b and Extended Data Fig. 1h , i). This indicated that core MCC could bind CDC20 associated with the APC/C, and that core rMCC did not compete with SBP CDC20 for APC/C binding ( Fig. 1c ). This agreed with our previous finding that the MCC and CDC20 bind to the APC/C through different sites 10 .
To determine the properties of MCC as an APC/C CDC20 inhibitor we used a reconstituted ubiquitylation assay with APC/C isolated from CDC20-depleted mitotic cells (APC/C DCDC20 ), and incubated it with SBP CDC20 and/or core rMCC. Adding CDC20 strongly activated the APC/C, whereas, as expected 6, 8 , core MCC alone only weakly stimulated the APC/C (Fig. 1d ). Neither MAD2 nor BUBR1 alone can inhibit the mitotic APC/C 11 , and together they require pre-incubation to inhibit interphase APC/C CDC20 (ref. 7) . By contrast, core MCC was a potent and rapid inhibitor of active APC/C CDC20 : as well as preventing CDC20 from activating the APC/C ( Fig. 1d and Extended Data Fig To gain insight into how core MCC could inhibit active APC/C CDC20 , we sought to identify how core MCC bound to a second CDC20. Studies on yeast MAD3/BUBR1 had implicated a number of D-box and KEN box motifs in binding to CDC20, and as important for the SAC 12, 13 . A D-box bound to the side of the CDC20 b-propeller domain in the MCC structure, whereas a KEN box bound to the top face 6 . We hypothesized that the second CDC20 might bind to the core MCC in a similar manner; therefore, we introduced mutations into the D-box receptor (D177A; DDR) and the KEN-box receptor (N329A/N331A/T377A/R445A; DKR) of CDC20. Both these CDC20 mutants bound much less well to core rMCC in vitro ( Fig. 2a, b ). Since the DDR mutant could still be incorporated into the core MCC ( Fig. 2c ), we tested whether inhibiting a second CDC20 was important for the SAC (Fig. 2d ). We replaced endogenous CDC20 with the DDR mutant, or the DKR mutant as a positive control, and assayed the ability of cells to arrest in response to nocodazole. As expected, the DKR mutant abrogated the SAC because it could not form the core MCC ( Fig. 2c-e ). By contrast, the DDR mutant assembled into the core MCC and bound to the APC/C ( Fig. 2c, d ), yet the SAC was still defective ( Fig. 2e ). Cells expressing the DDR mutant, however, took more time to exit mitosis than those expressing the DKR mutant ( Fig. 2e ). We thought this might be because the DDR mutant was less effective at activating the APC/C 14 ; consistent with this, cyclin B1 was degraded more slowly in these cells (Extended Data Fig. 4 ). These data supported the idea that the MCC inhibited a second CDC20 as part of a functional SAC.
Since CDC20 required its D-box and KEN box receptors to bind the core MCC, we identified the D-box and a KEN box on BUBR1 responsible for binding CDC20. The structure of the core MCC implicated a putative D-box 6 , but BUBR1 has two KEN-boxes: the first (K26EN) is essential to form the core MCC (Extended Data Fig. 1d ), whereas the second (K304EN) is not required to form the core MCC but is still important for the SAC 12, 13, 15, 16 . We thought the second KEN box a more likely candidate to bind a second CDC20 9 ; therefore, we mutated the putative D-box (R 224 xxL: DD-box) and the second KEN-box (DKEN2) in human BUBR1. Both mutants were incorporated into the core MCC in vitro ( Fig. 3a and Extended Data Fig. 5a ) and in vivo (Fig. 3c) ; both inhibited the CDC20 within the core MCC (Extended Data Fig. 5b ), but reduced binding to a second molecule of CDC20 ( Fig. 3a, b ). (Note that BUBR1 alone did not bind two molecules of CDC20 because neither the D-box nor the second KEN-box was required to bind CDC20 in the absence of MAD2 (Extended Data Fig. 5c ).) Furthermore, replacing endogenous BUBR1 with the DD-box mutant ( Fig. 3c ) prevented cells from arresting in mitosis in response to either nocodazole ( Fig. 3d ), or Taxol where the SAC is much weaker 17 (Extended Data Fig. 5d ). Thus, the core MCC must inhibit a second CDC20 molecule to impose a functional SAC.
An important test of our idea that the core MCC inhibited active APC/C CDC20 was whether the core MCC could arrest a mitotic cell in which kinetochores could not catalyse further CDC20 incorporation into the core MCC (see Extended Data Fig. 6a ). To prevent the core MCC from disassembling we attached a yellow fluorescent protein (YFP) tag to MAD2 (Venus-MAD2) and a green fluorescent protein (GFP)-binding domain (GBP) 18 to CDC20 (GBP-CDC20). We called this stable complex MCC M2 (see Extended Data Figs 6 and 7); a similar approach using leucine zippers had been used previously in budding yeast 19 . We expressed MCC M2 in cells with normal levels of endogenous CDC20. MCC M2 was able to inhibit the APC/C when the SAC was inactivated in three different ways: (1) MCC M2 imposed a metaphase delay ( Fig. 4a ), in which the kinetochores did not stain for MAD2 (Extended Data Fig. 8a ). The extent of the delay correlated with the amount of GBP-CDC20, and thus the amount of MCC M2 (Extended Data Fig. 8b); (2) MCC M2 imposed a delay in cells treated with the Mps1 kinase inhibitor reversine to prevent core MCC assembly 20 (Fig. 4b); (3) MCC M2 arrested cells in mitosis after depleting the KNL1 (also known as CASC5) kinetochore protein that 
No MCC formation
Time (h) Figure 2 | The MCC binds to CDC20 through substrate recognition domains. a, b, Mutating CDC20 substrate recognition domains reduces binding to rMCC. a, rMCC was incubated with in vitro translated (IVT) 33Flag-tagged wild-type CDC20, or CDC20 DDR , or CDC20 DKR mutants (indicated by *) and analysed as in Fig. 1a . DDR, D177 mutated to alanine; DKR, N329, N331, T377 and R445 mutated to alanine. b, Quantification of the data in panel a showing mean 6 s.e.m. of three independent biological replicates. c-e, Defective SAC in cells expressing a CDC20 mutant that weakly binds the MCC. c, HeLa cells expressing siRNA-resistant 33Flag-tagged CDC20 wild-type, or DKR, or DDR mutants, were treated with siRNA against CDC20, synchronized at prometaphase with nocodazole (Noc) and collected by mitotic shake-off. Anti-flag immunoprecipitates were analysed by quantitative immunoblotting. Results are representative of three biological replicates. Control cells (Ctrl) were depleted of GAPDH. End., endogenous. d, Schematic summary of CDC20 DDR and CDC20 DKR mutants. The CDC20 DDR mutant can form the MCC, but is only weakly bound and inhibited by the MCC. The CDC20 DKR mutant cannot form the MCC. e, HeLa cell lines of 3Flag-CDC20 were treated as in c, the time from nuclear envelope breakdown (NEBD) to mitotic exit measured, and plotted as a box and whisker chart where one diamond represents one cell. Red diamonds indicate the cell remained in mitosis until the end of the experiment. n, number of cells analysed in three independent experiments.
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is required for the SAC 21 (Extended Data Fig. 8c-e ). These data supported our idea that the core MCC inhibited active APC/C CDC20 . Moreover, as the MCC inhibits the APC/C without further signalling from the kinetochores, it has one of the essential properties required of the diffusible 'wait anaphase' inhibitor, although our data do not prove that it is the diffusible inhibitor in vivo.
All the functional components of the core MCC were required for MCC M2 to inhibit APC/C CDC20 because we could not delay cells in mitosis when we stabilized the binding between MAD2 and CDC20 in the absence of BUBR1 (Fig. 4c ), nor when we stabilized MAD2 with a CDC20-DKILR mutant that cannot form the core MCC (Extended Data Fig. 9a ). Finally, we stabilized the binding between MAD2 and CDC20 (MCC M2 ), but replaced BUBR1 with the DD-box mutant to perturb binding to a second CDC20. These complexes were much less effective at inhibiting APC/C CDC20 in vitro (Extended Data Fig. 9b ), and unable to delay cells in mitosis ( Fig. 4c ; model in Extended Data Fig. 9c ). Thus, we conclude that to arrest cells in mitosis the core MCC inhibits a second molecule of CDC20 that can even be part of an active APC/C CDC20 .
Crucial gaps have remained in our understanding of the SAC: notably, how the 'wait anaphase' signal generated at unattached kinetochores inhibits APC/C activity in the rest of the cell 2 . Unattached kinetochores appear to catalyse a conformational change in MAD2 to bind CDC20 22 and subsequently promote APC/C-MCC formation in the cytoplasm. However, it is unlikely that all CDC20 could be bound by MAD2 at the kinetochore, therefore additional mechanisms have been proposed to prevent the activation of the APC/C, including cytoplasmic amplification of MAD2-CDC20 binding 22 , although this now appears unlikely 19, 23 , and phosphorylation of CDC20 by BUB1 24 . We now show how the MCC, formed either at kinetochores or in the cytoplasm, could act as a diffusible inhibitor to inhibit APC/C CDC20 throughout the cell (Extended Data Fig. 10 ), although our data do not prove that it disseminates the 'wait anaphase' signal in vivo. Previously, it has been proposed 7 that the complex between MAD2 and CDC20 will template the formation of the BBC (BUBR1-BUB3-CDC20) complex 25 to inhibit CDC20-although in these experiments p31 Comet was depleted, which would alter the levels and behaviour of checkpoint complexes [25] [26] [27] . While we also find that the BBC is an abundant APC/C inhibitor in cells 27, 28 , we show here that stabilizing the MCC generates a more potent inhibitor than stabilizing the BBC (Fig. 4a ; MCC R1 see Extended Data Fig. 6b ), which agrees with the observation that cells containing a greater proportion of MCC over BBC exhibit stronger SAC activity 17, 25 . Our results could also solve a further conundrum posed by the SAC. MAD2 and the APC/C bind to the same KILR motif on CDC20 8 ; therefore, CDC20 must dissociate from the APC/C to bind MAD2. By analogy with measurements on Cdh1 29 , CDC20 is predicted to dissociate slowly from the APC/C (half time of dissociation ,25 min), yet reactivating the SAC can inhibit active APC/C in less than 5 min 3, 4 . Our finding that MCC rapidly inhibits CDC20 already bound to the APC/C can help to explain the close temporal coupling between the SAC and the APC/C. Indeed, our data indicate that the MCC prefers CDC20 that is already bound to the APC/C; the reason for this will be important to determine in the future. and this is required for the SAC. a, b, The D-box and second KEN box of BUBR1 bind to CDC20. a, rMCC containing SBP BUBR1 wild-type, or DD-box, or DKEN2 (indicated by *), was incubated with 33Flag-tagged CDC20 (IVT) and analysed as in a. DD-box, R224A, L226A; DKEN2, K304EN mutated to AAA. b, Quantification of the data in panel a to show the mean 6 s.e.m. of four independent biological replicates. c, The D-box mutant of BUBR1 forms the MCC. HeLa cells expressing siRNA-resistant 33Flag-Cerulean-BUBR1 (3F-Ce-BUBR1), either wild-type or the DD-box mutant, were treated with siRNA against BUBR1, and prometaphase cells collected by mitotic shake off and analysed as in Fig. 2c . Result is representative of three biological replicates. d, The D-box of BUBR1 is required for the SAC. HeLa cell lines expressing wild-type and DD-box mutant 3F-Ce-BubR1 were treated as in c, 0.33 mM nocodazole was added and the time from NEBD to mitotic exit was measured as in Fig. 2e . n, number of analysed cells from two independent biological replicates. Note that the DD-box mutation did not affect the recruitment of BUBR1 to unattached kinetochores (Extended Data Fig. 5e ). Figure 4 | A stabilized MCC delays anaphase by inhibiting endogenous APC/C CDC20 . a, HeLa cells were transfected with plasmids encoding mCherry-GBP-CDC20 and either Venus-MAD2 or Venus-BUBR1, and the time from NEBD to anaphase was analysed in unperturbed mitoses as in Fig. 2e . n, number of cells from three independent biological replicates. b, HeLa cell lines stably expressing mCherry-GBP-CDC20 and a tetracyclin-inducible 33Flag-Venus-MAD2 were treated, or not, with 1 mM reversine (1Rev) 6 h after release from a thymidine block in the presence (1Tet) or absence (2Tet) of tetracyclin, and analysed as in a. n, number of cells from two independent biological replicates. c, HeLa cells lines in Fig. 3c expressing 3F-Ce-BUBR1 plus mCherry-GBP-CDC20 and Venus-MAD2 were treated with siRNA against BUBR1 and analysed as in panel a. n, number of cells from two independent biological replicates.
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Extended Data Figure 1 | Recombinant human mitotic checkpoint complex binds to a second CDC20. a, Schematic illustration of purification steps. Human wild-type CDC20 (untagged), SBP BUBR1 and 6His MAD2 were expressed in baculovirus-infected Sf9 cells. The recombinant core mitotic checkpoint complex (rMCC) was purified by nitrilotriacetic acid (Ni-NTA) and streptavidin beads. Purified core rMCC bound to streptavidin beads was used to assay binding to purified recombinant Cdc20. b, Core rMCC consisting of CDC20, SBP BUBR1 and 6His MAD2 was analysed by SDS-PAGE and Coomassie blue R250 staining, followed by quantification at 680 nm on a LiCOR Odyssey scanner. Equal molar amounts of purified SBP BUBR1, SBP CDC20 and SBP MAD2 proteins were used to calibrate the Coomassie blue staining. The stoichiometry of core rMCC (mean 6 s.d. is shown below the panel with SBP BUBR1 set to 1.0) was estimated from three independently purified core rMCC preparations. Molecular mass markers are on the left. c, d, Both the MAD2 binding motif of CDC20 and the first KEN box of BUBR1 are required to assemble rMCC. Core rMCC was pulled down with streptavidin beads from Sf9 cells expressing SBP BUBR1, 6His MAD2 and either wild-type (WT) CDC20 or the K129ILR/AAAA mutant (DKILR) (c), or 6His MAD2, wild-type CDC20 plus wild-type SBP BUBR1, or alanine substitution mutants of either KEN box 1 (DKEN1) or KEN box 2 (DKEN2). The proteins retained on streptavidin beads were analysed by immunoblotting with the indicated antibodies. e, Relative expression levels of core rMCC components. Sf9 cells extracts expressing the core rMCC, and the purified rMCC complex, were analysed by quantitative immunoblotting. The ratio of the proteins in the extracts is given, with that of SBP BUBR1 set to 1.0. f, Schematic illustration of the second CDC20 binding assay in Fig. 1a . In lanes 1 and 2, the streptavidin beads were incubated with either 6His CDC20 wild-type or the DKILR (K129ILR/AAAA) mutant. In lanes 3 and 4, the streptavidin beads bound to core rMCC were incubated with the 6His CDC20 proteins. In lanes 6 and 7, the streptavidin beads bound to 6His-SBP CDC20 were incubated with the 6His CDC20 proteins. g, Sf9 cell extracts expressing core rMCC or 3Flag-tagged CDC20 were mixed and the core rMCC purified as in a. The core rMCC was analysed by quantitative immunoblotting. 51% of the core rMCC was purified bound to a second 3Flag CDC20. h, A functional CDC20 promotes the binding of core rMCC to the APC/C. The APC/C was immunoprecipitated from CDC20-depleted mitotic extracts supplemented with a constant amount of core rMCC and tenfold excess of recombinant wild-type SBP CDC20, or the DKILR or DIR mutants. The co-immunoprecipitates were analysed as in Fig. 1c . i, Schematic of the APC/C-MCC-CDC20 ternary complex. Both core rMCC and CDC20 bind to the APC/C and form a ternary complex (left). The CDC20 DKILR mutant cannot bind the APC/C directly, nor stimulate core rMCC binding to the APC/C, but CDC20 DKILR still binds to rMCC (right). All results are representative of two or more independent biological replicates.
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Extended Data Figure 5 | Characterization of the MCC containing D-box or KEN box 2 mutants of BUBR1. a, Core rMCC assembled with SBP BUBR1 wild type, or DD-box, or DKEN2 mutants, was purified as in Extended Data Fig. 1a, b and analysed on a LiCOR Odyssey scanner at 680 nm after SDS-PAGE and Coomassie blue R250 staining. b, The core rMCC mutants prepared in a were assayed as APC/C inhibitors in an in vitro ubiquitylation assay as in Fig. 1d . c, Insect cell extracts expressing CDC20 with SBP BUBR1, either wild type, or DD-box or DKEN2 mutants, were incubated with streptavidin beads. The proteins retained on the streptavidin beads were analysed by quantitative immunoblotting. Results in panels a-c are representative of two independent biological replicates. d, HeLa cells were treated with siRNA against BUBR1 and rescued with 33Flag-Cerulean-BUBR1, either wild-type or the DD-box mutant, and mitosis analysed in 0.116 mM Taxol as in Fig. 3d . The time from NEBD to anaphase (or mitotic exit) was measured and plotted as a box and whisker chart. n, number of analysed cells from two independent biological replicates. e, HeLa cells were treated with siRNA against BUBR1 and rescued with siRNA resistant 33Flag-Cerulean-BUBR1, either wild type or the DD-box mutant, then analysed by immunostaining. Cells were stained with anti-Flag M2 and anti-ACA antibodies, and Hoechst 33342, and representative images of prometaphase cells from two independent biological replicates are shown. Scale bar, 10 mm.

